Information:
Fel:
Nyckelord
Amyloidoosi ×
- Clinical Trial (6)
- Quality of Life (2)
- Transplantation (1)
- Stem Cell Transplantation (1)
- Baseline (1)
- On-Study Form (1)
- General report (1)
- Disease Response (1)
- Routine documentation (1)
- Eligibility Determination (1)
- Follow-Up Studies (1)
Innehållsförteckning
Valda datamodeller
Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.
10 Sökresultat.
Item-grupper: Demographic Factors, Comorbidities, Patient reported outcomes: ATTR Diagnosis, First organ system involved, Patient reported outcomes: Quality of life, Patient reported outcomes: Disability, Patient reported Outcomes: ATTR Management, ATTR Therapy
Item-grupper: GENERAL INFORMATION TEAM, GENERAL INFORMATION PATIENT, DISEASE, AL AMYLOIDOSIS INITIAL DIAGNOSIS, ORGAN INVOLVEMENT AT DIAGNOSIS, PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION (AUTOGRAFTS ONLY), STATUS OF DISEASE AT START OF CONDITIONING FOR BMT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, ORGAN-SPECIFIC RESPONSES AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, FOLLOW UP AL AMYLOIDOSIS, PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, GRAFT ASSESSMENT AND HAEMOPOIETIC CHIMAERISM, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF DISEASE WORSENING SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS, ADDITIONAL NOTES IF APPLICABLE
Item-grupper: GENERAL INFORMATION TEAM, GENERAL INFORMATION PATIENT, DISEASE, AL AMYLOIDOSIS INITIAL DIAGNOSIS, ORGAN INVOLVEMENT AT DIAGNOSIS, PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION (AUTOGRAFTS ONLY), STATUS OF DISEASE AT START OF CONDITIONING FOR BMT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, ORGAN-SPECIFIC RESPONSES AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, FOLLOW UP AL AMYLOIDOSIS, PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, GRAFT ASSESSMENT AND HAEMOPOIETIC CHIMAERISM, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF DISEASE WORSENING SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS, ADDITIONAL NOTES IF APPLICABLE
Item-grupper: Inclusion Criteria, Exclusion Criteria
Item-grupper: Demographic Factors, Patient reported outcomes: Quality of life, Patient reported outcomes: Disability
Item-grupper: GENERAL INFORMATION TEAM, GENERAL INFORMATION PATIENT, DISEASE, AL AMYLOIDOSIS INITIAL DIAGNOSIS, ORGAN INVOLVEMENT AT DIAGNOSIS, PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION (AUTOGRAFTS ONLY), STATUS OF DISEASE AT START OF CONDITIONING FOR BMT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, ORGAN-SPECIFIC RESPONSES AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, FOLLOW UP AL AMYLOIDOSIS, PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, GRAFT ASSESSMENT AND HAEMOPOIETIC CHIMAERISM, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF DISEASE WORSENING SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS, ADDITIONAL NOTES IF APPLICABLE
Item-grupper: Header, Amyloid: Form Administration, Amyloid: Disease Description, Amyloid: Prior Treatment
Item-grupper: CRF Header, Amyloid: Form Administration, Amyloid: Assessment Reporting Interval, Amyloid: Protein Studies, Amyloid: Peripheral Blood Hematology/Chemistry, Amyloid: Organ Assessment, Amyloid: Bone Marrow Assessment, Amyloid: Amyloidoma, Comments
Item-grupper: CRF Header, Amyloid: Form Administration, Amyloid: Assessment Reporting Interval, Amyloid: Protein Studies, Amyloid: Peripheral Blood Hematology/Chemistry, Amyloid: Organ Assessment, Amyloid: Bone Marrow Assessment, Amyloid: Amyloidoma, Amyloid: Objective Response Assessment, Comments
Item-grupper: CRF Header, Amyloidosis: Vital Status, Amyloidosis: Disease Follow-Up Status, Amyloidosis: Notice of Progression, Amyloidosis: Notice of New Primary, Amyloidosis: Long-Term Toxicity